Search results
Showing 651 to 700 of 1516 results for patients and public
This guideline covers the diagnosis and management of gout. It includes recommendations on diagnosing gout, managing flares, long-term management of gout and referral to specialist services.
Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism (TA287)
Evidence-based recommendations on rivaroxaban (Xarelto) for treating pulmonary embolism and for preventing a further deep vein thrombosis or pulmonary embolism in adults.
Birch bark extract for treating epidermolysis bullosa (HST28)
Evidence-based recommendations on birch bark extract (Filsuvez) for treating partial thickness wounds associated with dystrophic and junctional epidermolysis bullosa in people aged 6 months and over.
Rifaximin for preventing episodes of overt hepatic encephalopathy (TA337)
Evidence-based recommendations on rifaximin (Targaxan) for preventing episodes of hepatic encephalopathy in adults.
Evidence-based recommendations on palbociclib (Ibrance) with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy.
People have the right to be able to make informed decisions about their care. Our guidance should be taken into account when making decisions with them.
Antimicrobial prescribing: eravacycline for complicated intra-abdominal infections in adults (ES40)
Summary of the evidence on eravacycline for complicated intra-abdominal infections in adults
Thoracoscopic aortopexy for severe primary tracheomalacia (HTG156)
Evidence-based recommendations on thoracoscopic aortopexy for severe primary tracheomalacia. This involves attaching the aorta to the sternum with sutures, using special instruments through small cuts in the chest (keyhole surgery).
View recommendations for HTG156Show all sections
Sections for HTG156
Evidence-based recommendations on certolizumab pegol (Cimzia) for treating severe active rheumatoid arthritis in adults who have had a tumour necrosis factor-alpha inhibitor.
Evidence-based recommendations on enzalutamide (Xtandi) for treating metastatic hormone-relapsed prostate cancer in adults who have had treatment with docetaxel-containing chemotherapy.
This guideline covers targeted interventions to prevent misuse of drugs, including illegal drugs, ‘legal highs’ and prescription-only medicines. It aims to prevent or delay harmful use of drugs in children, young people and adults who are most likely to start using drugs or who are already experimenting or using drugs occasionally.
This guideline covers systems and processes for using and managing controlled drugs safely in all NHS settings except care homes. It aims to improve working practices to comply with legislation and have robust governance arrangements. It also aims to reduce the safety risks associated with controlled drugs.
Digital tools and platforms to support the early detection and initial diagnosis of hearing loss
Awaiting development Reference number: GID-HTE10088 Expected publication date: TBC
Awaiting development Reference number: GID-HTE10083 Expected publication date: TBC
Digital AI tools in histopathology (breast and prostate cancer)
Awaiting development Reference number: GID-HTE10087 Expected publication date: TBC
Insertion of pleuro–amniotic shunt for fetal pleural effusion (HTG123)
Evidence-based recommendations on inserting a pleuro-amniotic shunt to drain pleural effusions in a fetus during pregnancy. This involves inserting a drainage tube through the fetal chest wall into the pleural space, allowing fluid to drain into the amniotic cavity.
View recommendations for HTG123Show all sections
Sections for HTG123
Prevention of chemotherapy induced nausea and vomiting in adults: netupitant/palonosetron (ESNM69)
Summary of the evidence on netupitant/palonosetron to prevent chemotherapy induced nausea and vomiting to inform local NHS planning and decision-making
Summary of the evidence on topical timolol for treating infantile haemangioma (strawberry marks) to inform local NHS planning and decision-making
This guideline covers assessment, treatment, monitoring and inpatient care for children, young people and adults with eating disorders. It aims to improve the care people receive by detailing the most effective treatments for anorexia nervosa, binge eating disorder and bulimia nervosa.
treating cystic fibrosis patients with: Ivacaftor, tezacaftor and elexacaftor (Kaftrio®) in combination with ivacaftor for...
The Sonata Treatment - Transcervical Radiofrequency Fibroid Ablation using Intrauterine Ultrasound
Awaiting development Reference number: GID-MT603 Expected publication date: TBC
Artificial intelligence technologies for mammography: early value assessment
Awaiting development Reference number: GID-HTE10062 Expected publication date: TBC
Evidence-based recommendations on atezolizumab (Tecentriq) for untreated PD-L1-positive locally advanced or metastatic urothelial cancer in adults when cisplatin-containing chemotherapy is unsuitable.
Benegrastim for treating chemotherapy-induced neutropenia in people with breast cancer [TSID11769]
Awaiting development Reference number: GID-TA11088 Expected publication date: TBC
Awaiting development Reference number: GID-IPG10419 Expected publication date: TBC
NICE's guidance executive is made up of executive directors, guidance centre directors and senior team members.
Cellulitis and erysipelas: antimicrobial prescribing (NG141)
This guideline sets out an antimicrobial prescribing strategy for adults, young people, children and babies aged 72 hours and over with cellulitis and erysipelas. It aims to optimise antibiotic use and reduce antibiotic resistance.
Awaiting development Reference number: GID-TA11691 Expected publication date: TBC
Awaiting development Reference number: GID-IPG10409 Expected publication date: TBC
Transvaginal Ultrasound-Guided Radiofrequency Ablation (RFA) for Uterine Fibroids
Awaiting development Reference number: GID-IPG10465 Expected publication date: TBC
Awaiting development Reference number: GID-TA10833 Expected publication date: TBC
Awaiting development Reference number: GID-TA11705 Expected publication date: TBC
Extravascular implantable cardioverter defibrillator insertion for preventing sudden cardiac death
Awaiting development Reference number: GID-IPG10437 Expected publication date: TBC
Depth of anaesthesia monitors – Bispectral Index (BIS), E-Entropy and Narcotrend-Compact M (HTG292)
Evidence-based recommendations on 3 electroencephalography (EEG)-based depth of anaesthesia monitors for assessing a patient’s response to anaesthetic drugs during surgery. The monitors are Bispectral Index (BIS), E-Entrophy and Narcotrend-Compact M.
Evidence-based recommendations on sofosbuvir (Sovaldi) for treating some types of chronic hepatitis C (HCV)
View recommendations for TA330Show all sections
Tirzepatide for treating type 2 diabetes in people 10 to 17 years [ID6539]
Awaiting development Reference number: GID-TA11700 Expected publication date: TBC
Awaiting development Reference number: GID-TA11150 Expected publication date: TBC
Awaiting development Reference number: GID-TA11332 Expected publication date: TBC
Sevabertinib for untreated HER2-positive advanced non-small-cell lung cancer [ID6616]
Awaiting development Reference number: GID-TA11814 Expected publication date: TBC
Awaiting development Reference number: GID-TA11792 Expected publication date: TBC
Awaiting development Reference number: GID-TA11717 Expected publication date: TBC
Tildrakizumab for treating active psoriatic arthritis [TSID12218]
Awaiting development Reference number: GID-TA11807 Expected publication date: TBC
Awaiting development Reference number: GID-TA11752 Expected publication date: TBC
Awaiting development Reference number: GID-TA11698 Expected publication date: TBC
Tasimelteon for treating sleep disturbance associated with Smith-Magenis syndrome [TSID12191]
Awaiting development Reference number: GID-TA11746 Expected publication date: TBC
Awaiting development Reference number: GID-TA11778 Expected publication date: TBC
Ruxolitinib for treating moderate atopic dermatitis [ID6602]
Awaiting development Reference number: GID-TA11809 Expected publication date: TBC
Awaiting development Reference number: GID-TA11623 Expected publication date: TBC
Awaiting development Reference number: GID-TA11751 Expected publication date: TBC
Awaiting development Reference number: GID-TA11820 Expected publication date: TBC